blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3004877

EP3004877 - COMPOSITIONS AND METHODS FOR IDENTIFICATION, ASSESSMENT PREVENTION, AND TREATMENT OF CANCER USING PD-L1 ISOFORMS [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  03.08.2018
Database last updated on 24.08.2024
FormerExamination is in progress
Status updated on  10.11.2017
Most recent event   Tooltip03.08.2018Application deemed to be withdrawnpublished on 05.09.2018  [2018/36]
Applicant(s)For all designated states
Dana-Farber Cancer Institute, Inc.
450 Brookline Avenue
Boston MA 02459 / US
[2016/15]
Inventor(s)01 / HAMMERMAN, Peter
217 Greenwood Street
Newton, MA 02459 / US
 [2016/15]
Representative(s)Helbig, Christian
Wagner + Helbig Patentanwälte Pfarrstrasse 14
80538 München / DE
[2016/15]
Application number, filing date14807512.002.06.2014
[2016/15]
WO2014US40504
Priority number, dateUS201361831894P06.06.2013         Original published format: US 201361831894 P
[2016/15]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014197369
Date:11.12.2014
Language:EN
[2014/50]
Type: A1 Application with search report 
No.:EP3004877
Date:13.04.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 11.12.2014 takes the place of the publication of the European patent application.
[2016/15]
Search report(s)International search report - published on:US11.12.2014
(Supplementary) European search report - dispatched on:EP17.03.2017
ClassificationIPC:G01N33/50, C12Q1/68
[2017/02]
CPC:
C12Q1/6886 (EP,US); A61P35/00 (EP); G01N33/57407 (EP,US);
G01N33/57423 (EP,US); G01N33/57492 (US); C12N15/1138 (US);
C12N2310/11 (US); C12N2320/30 (US); C12Q2600/106 (EP,US);
C12Q2600/112 (EP,US); C12Q2600/118 (EP,US); C12Q2600/156 (EP,US);
C12Q2600/158 (EP,US); G01N2333/4703 (US); G01N2333/70503 (US);
G01N2333/70596 (EP,US); G01N2500/00 (EP,US); G01N2500/04 (US);
G01N2500/10 (US); G01N2800/50 (EP,US); G01N2800/52 (EP,US) (-)
Former IPC [2016/15]G01N33/50
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/15]
TitleGerman:ZUSAMMENSETZUNGEN UND VERFAHREN ZUR IDENTIFIKATION, BEURTEILUNG, VORBEUGUNG UND BEHANDLUNG VON KREBS MIT PD-L1-ISOFORMEN[2016/15]
English:COMPOSITIONS AND METHODS FOR IDENTIFICATION, ASSESSMENT PREVENTION, AND TREATMENT OF CANCER USING PD-L1 ISOFORMS[2016/15]
French:COMPOSITIONS ET PROCÉDÉS D'IDENTIFICATION, D'ÉVALUATION, DE PRÉVENTION ET DE TRAITEMENT DU CANCER EN UTILISANT DES ISOFORMES PD-L1[2016/15]
Entry into regional phase04.01.2016National basic fee paid 
04.01.2016Search fee paid 
04.01.2016Designation fee(s) paid 
04.01.2016Examination fee paid 
Examination procedure04.01.2016Examination requested  [2016/15]
13.10.2017Amendment by applicant (claims and/or description)
14.11.2017Despatch of a communication from the examining division (Time limit: M04)
27.03.2018Application deemed to be withdrawn, date of legal effect  [2018/36]
25.04.2018Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2018/36]
Divisional application(s)EP17197526.1  / EP3293275
Fees paidRenewal fee
27.06.2016Renewal fee patent year 03
27.06.2017Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XI]  - YAN ZHANG ET AL, "Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer", CELLULAR & MOLECULAR IMMUNOLOGY, CH, (20100531), vol. 7, no. 5, doi:10.1038/cmi.2010.28, ISSN 1672-7681, pages 389 - 395, XP055326497 [X] 9,11,12 * abstract * * Results, first section.;; figure 1 * [I] 1-8,10,13-15

DOI:   http://dx.doi.org/10.1038/cmi.2010.28
 [XI]  - S. LYFORD-PIKE ET AL, "Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma", CANCER RESEARCH, (20130103), vol. 73, no. 6, doi:10.1158/0008-5472.CAN-12-2384, ISSN 0008-5472, pages 1733 - 1741, XP055179352 [X] 9,11,12 * abstract * * page 1736; figure 2 * [I] 1-8,10,13-15

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-12-2384
 [XI]  - SARA I. PAI, "Adaptive immune resistance in HPV-associated head and neck squamous cell carcinoma", ONCOIMMUNOLOGY, (20130501), vol. 2, no. 5, doi:10.4161/onci.24065, page e24065, XP055326362 [X] 9,11,12 * page e24065, column 2, paragraph 1 * [I] 1-8,10,13-15

DOI:   http://dx.doi.org/10.4161/onci.24065
 [XI]  - C. BADOUAL ET AL, "PD-1-Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer", CANCER RESEARCH, US, (20121107), vol. 73, no. 1, doi:10.1158/0008-5472.CAN-12-2606, ISSN 0008-5472, pages 128 - 138, XP055326633 [X] 9,11,12 * abstract * [I] 1-8,10,13-15

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-12-2606
 [XI]  - Suzanne L Topalian ET AL, "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer", The New England journal of medicine, United States, doi:10.1056/NEJMoa1200690, (20120628), pages 2443 - 2454, URL: http://search.proquest.com/docview/1022620071, XP055098235 [X] 9,11,12 * abstract * [I] 1-8,10,13-15

DOI:   http://dx.doi.org/10.1056/NEJMoa1200690
International search[X]US2011033884  (WOOD CLIVE [US], et al) [X] 1-60 * entire document *;
 [A]WO2011049603  (DANA FARBER CANCER INST INC [US], et al) [A] 1-60 * entire document *;
 [A]US2011271358  (FREEMAN GORDON J [US], et al) [A] 1-60 * ) entire document *;
 [A]US2012237522  (KANG CHANG YUIL [KR], et al) [A] 1-60 * entire document *;
 [A]  - GRZYWNOWICZ et al., "Programmed Death-1 and Its Ligand Are Novel Immunotolerant Molecules Expressed on Leukemic B Cells in Chronic Lymphocytic Leukemia", PLoS One, vol. 7, no. Iss. 4, pages 1 - 7, XP055300125 [A] 1-60 * . entire document *

DOI:   http://dx.doi.org/10.1371/journal.pone.0035178
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.